An Expanded Access Study of NeuroVax for Multiple Sclerosis Patients
Latest Information Update: 26 Apr 2019
At a glance
- Drugs IR 902 (Primary)
- Indications Multiple sclerosis
- Focus Expanded access; Therapeutic Use
Most Recent Events
- 26 Apr 2019 New trial record
- 23 Apr 2019 According to an Immune Response BioPharma media release, the company expects that robust patients may only enroll via Immune Response Website: IRBP.It changed compensation to unlimited income per patient per injection no cap: patient will receive vaccine and payment for 500 patients enrolled. Once study enrollment is reached no additional patients will be allowed to participate due to low supply of vaccine.
- 23 Apr 2019 According to an Immune Response BioPharma media release, the company expects NeuroVax to be oversubscribed right to try, enrollment picking up steam.